Epic Sciences

Press Releases

11.05.2018

Epic Sciences Joins Forces with Canadian Consortium of Investigators to Predict Late Recurrence of Metastatic Breast Cancer

Epic Sciences is collaborating with four major breast cancer centers on a clinical trial to determine if Epic’s blood test can be used to predict which women, who have already been treated for localized breast cancer, are at risk of late recurrence of metastatic breast cancer.

10.29.2018

Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer, Effective December 10

Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage.

09.24.2018

Epic Sciences Announces Publication Showing Blood Test Could Help Select Metastatic Prostate Cancer Patients Who Respond to PSMA-Targeted Therapies

Epic Sciences, in partnership with Memorial Sloan Kettering (MSK), have demonstrated that a liquid biopsy blood test may be used in clinical trials to find patients who are likely to benefit from PSMA-targeted therapies, before treatment is initiated.

09.12.2018

Epic Sciences Announces Completion of $52 Million Series E Financing

Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR).

09.04.2018

Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer

Epic Sciences (Epic), the maker of the world’s first predictive test of drug response in prostate cancer, announced the expansion of its leadership team with the appointment of Katherine Atkinson as chief commercial officer. 

More Press Releases

In the News

11.12.2018

Video - New test extending lives of advanced prostate cancer patients

Bryce Olson discusses the Oncotype DX® AR-V7 Nucleus Detect™ test, developed by Epic Sciences and commercially available through Genomic Health, with ABC 10 News. The test determines which men with late-stage metastatic prostate cancer will benefit from AR-targeted therapy or chemotherapy.

11.06.2018

Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted Therapies

San Diego, CLP Magazine — In a study sponsored by Epic Sciences, San Diego, in partnership with Memorial Sloan Kettering Cancer Center, researchers have demonstrated that a liquid biopsy blood test may be used before treatment is initiated in clinical trials to find patients who are likely to benefit from therapies targeting prostate-specific membrane antigen.

11.05.2018

Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium

New York, GenomeWeb – Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients.

10.29.2018

Epic Sciences, Genomic Health Get Medicare LCD for Prostate Cancer Diagnostic

San Diego, Clinical OMICs – Epic Sciences and Genomic Health announced that Medicare Administrative Contractor Palmetto GBA, has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage effective December 10, 2018.

10.03.2018

Epic Sciences Continues Research on Multiple Fronts; Remains Quiet on Dx Development Pipeline

New York, GenomeWeb – With its first commercial diagnostic now fully launched and awaiting a final coverage decision by Medicare, Epic Sciences is keeping quiet about concrete plans for a pipeline of additional clinical assays, though it continues to collect data from research studies which may provide possibilities for future translation.

More News